LARS1 and cancer: As dysregulation of these checkpoint pathways induces development of diverse pathologies such as auto-immune diseases or cancers (40–42), understanding the mechanisms by which CLRs are triggered, beyond cell death, can pave the way for future targeting therapies (42, 134–136).